The U.S. Food and Drug Administration has approved Bristol Myers Squibb’s Breyanzi (lisocabtagene maraleucel; liso-cel), a CD19-directed CAR T cell therapy, for adults with relapsed or refractory marginal zone lymphoma who have received at least two prior lines of systemic therapy. Breyanzi is administered as a one-time infusion. “The FDA approval of Breyanzi for relapsed or refractory marginal zone lymphoma further solidifies it as the leading CD19-directed CAR T cell therapy covering the br...